News briefing: Five Prime finalizes PhIII plans for gastric cancer; AI diagnostics-focused Paige expands staff
Five Prime Therapeutics has finalized a plan to take their comeback gastric cancer drug into late-stage studies.
The South San Francisco-based biotech
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
